Director's Dealing

RNS Number : 6620D

OptiBiotix Health PLC

11 October 2018

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Director's Dealing

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 10 October 2018 that Mrs Carol Anne Christie, wife of Mr Sean Christie, a Non-Executive Director of the Company, acquired 125,000 ordinary shares in the Company on 10 October 2018, representing 0.15% of the Company's issued share capital, at a price of 80 pence per share and will be held in the name of Mrs Carol Anne Christie. Prior to the transaction, neither Mr Christie nor Mrs Christie held ordinary shares in the Company.

Under the AIM Rules for Companies, Mrs Carol Anne Christie is considered a related party and therefore this transaction or any further transactions must be disclosed under the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / Jo Turner
finnCap (Broker)		Tel: [phone]
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Carol Anne Christie
2	Reason for notification
a.	Position/Status	Wife of Mr Sean Christie, a Non-Executive Director of the Company
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	OptiBiotix Health Plc
b.	LEI	213800UKYQFT941QHS14
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	125,000 ordinary shares of 2p each ISIN: GB00BP0RTP38
b.	Nature of the transaction	Purchase of 125,000 ordinary shares in the Company. Following the transaction, Mrs Carol Anne Christie has an interest in 125,000 ordinary shares in the Company. Mr Sean Christie holds options over 100,000 ordinary shares in the Company.
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			80p	125,000
d.	Aggregated information - Aggregated Volume - Price	125,000 80p
e.	Date of the transaction	10 October 2018
f.	Place of the transaction	London Stock Exchange, AIM

 

END

 

 

DSHDBLFFVBFLFBX